Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Innovation Pharmaceuticals Inc IPIX

Innovation Pharmaceuticals Inc. is a clinical-stage pharmaceutical company. The Company is engaged in the business of developing or licensing small molecule therapies. The Company’s lead drug candidate, Brilacidin, is in a class of compounds called defensin-mimetics, small compounds that mimic the structure and function of defensins, also known as host defense peptides. The Company’s efforts are primarily focused on business development for the advancement of Brilacidin. It is primarily focused on advancement of its drug candidate Brilacidin for decreasing the incidence of severe oral mucositis as a complication of chemoradiation in oral mucositis. The Company also owns an interest in BT BeaMedical Technologies Ltd. (BTL), a private company developing an image guided surgical laser platform. The Company is monitoring BTL’s progress in advancing its laser-based thermal ablation technology platform targeting epilepsy and oncology procedures.


GREY:IPIX - Post by User

Post by Brito1on Sep 15, 2020 2:25pm
141 Views
Post# 31561018

Regarding todays news

Regarding todays news
Great Post by Fat Albert at the swamp: Anyone see a connection? Leo puts out a PR about Kevetrin's ability to arrest cell growth in AML cells. Kevetrin further shown to exhibit preferential cytotoxic activity against leukemia blast cells while largely not affecting the immune microenvironment, supporting a less toxic drug profile. As a gene-based therapy, should Kevetrin demonstrate efficacy in clinical testing, its regulatory pathway to approval might be expedited. The Food and Drug Administration (FDA) has signaled strong support for development of gene therapies. Two gene therapies for cancers of the blood (Kymriah and Yescarta) were approved for genetically-driven diseases based primarily on results from mid-stage, single-arm, open-label clinical trials. FDAs efficacy determination for Kymriah was based on 92 evaluable patients, and 108 evaluable patients for Yescarta. https://www.yescartatecartusrems.com/ Yescarta/Tecartus used in conjunction within REMS program. Owned by Kite Pharma, Inc. a Gilead Company. * Gilead owns Remdesivir which works great in conjunction with Brilacidin. * Gilead is in the Lymphoma fighting business through Kite Pharma (Tecartus against MCL). * Kevetrin shown to be a promising therapeutic against TP53-mutant AML. * B has been proven to help against cytokines storms * Gilead just purchased Immunomedics which is highly vested in the research to fight different types of cancers. IPIX has the most promising p53 modulator and the most promising defensin-mimetic. This is a match made in heaven!!!! Gilead can further enhance it's lymphoma fighting pipeline with Keventrin while utilizing Brilacidin in conjunction with Remdesivir and their AML and MCL drugs that have cytokines storm reactions. I think Gilead is making a play! Read More: https://investorshangout.com/post/view?id=5894567#ixzz6Y8UheuxX
<< Previous
Bullboard Posts
Next >>